The Super Patch Sleep Study Released

COLORADO SPRINGS, Colo. - May 2, 2025 - PRLog -- A study to be presented at the Sleep Europe Congress in Seville, Spain, highlights the effectiveness of a non-pharmacological, vibrotactile trigger technology (VTT)-embedded sleep patch in improving sleep quality, duration, and reducing insomnia-related symptoms. The study, part of the HARMONI trial, showed that patients using the VTT-embedded patch experienced improvements in sleep measures and overall quality of life, with many preferring the patch over traditional oral medications.
Key Takeaways:

1. Sleep Improvements: The study found that the vibrotactile sleep patch led to statistically significant improvements in sleep quality, duration, and a reduction in the time it takes to fall asleep.
2. Reduction in Medication Use: After 14 days of using the patch, most patients in the treatment group reported a reduction in the use of oral medications.
3. Enhanced Quality of Life: The study also showed positive outcomes in quality of life, with patients reporting reduced daytime fatigue and better mood, concentration, and ability to perform daily tasks.

The Super Patch Company will present its latest research on its non-pharmacologic, haptic vibrotactile trigger technology (VTT)-embedded topical patch to reduce sleep- and insomnia-related issues or associated symptoms at the Sleep Europe Congress in Seville, Spain, from Sept 24-27.
Data being presented by study investigators will include results from the HARMONI trial sharing patient outcomes and changes relating to sleep quality, sleep duration, quality-of-life components, and the use of concurrent medications after using the non-invasive, non-pharmacological topical patch with VTT.
Vibrotactile technology is a contact-based technology. When the pattern touches the skin, it triggers a sensation and sends information to the brain. The brain and nervous system process that information, potentially leading to wellness benefits.
"For over a decade, we have been researching the effects of haptic technology for multiple therapeutic conditions and wellness applications. We are excited to share the most recent data about our sleep patch with clinicians from around the world. Based on these results and ongoing randomized controlled trials, we believe that our VTT patches could offer a viable alternative and be added to current approaches and treatments of non-invasive and non-pharmacological sleep therapies with minimal side effects," says Jay Dhaliwal, founder and CEO of Super Patch, in a release.

Study Using the VTT-Embedded Sleep Patch

Learn More:  http://www.bobbybrownbiz.com